Uptake and predictors of colonoscopy use in family members not participating in cascade genetic testing for Lynch syndrome.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 09 2020
Historique:
received: 13 02 2020
accepted: 03 09 2020
entrez: 30 9 2020
pubmed: 1 10 2020
medline: 5 1 2021
Statut: epublish

Résumé

Cascade genetic testing provides a method to appropriately focus colonoscopy use in families with Lynch syndrome (LS). However, research suggests that up to two-thirds at risk to inherit LS don't participate. Within the United States, no studies have assessed colonoscopy use within this elusive and high-risk subset. We set forth to (1) document colonoscopy use within those not undergoing genetic testing (NGT) and (2) identify factors associated with completing colonoscopy. Data came from a cross sectional survey of families with molecularly confirmed LS. One hundred seventy-six (176) adults participated; 47 of unknown variant status and 129 with variant status known (59 carriers/70 non-carriers). Despite a high level of awareness of LS (85%) and identical recommendations for colonoscopy, NGT reported significantly lower use of colonoscopy than carriers (47% vs. 73%; p = 0.003). Our results show that perceived risk to develop colon cancer (AOR = 1.99, p < 0.05) and physician recommendations (AOR = 7.64, p < 0.01) are significant predictors of colonoscopy use across all family members controlling for carrier status. Given these findings, health care providers, should assess patients' perceived risk to develop cancer, assist them in adjusting risk perceptions and discuss recommendations for colonoscopy with all members in families with LS.Trial Registration Clinical Trials.gov Identifier: NCT00004210.

Identifiants

pubmed: 32994442
doi: 10.1038/s41598-020-72938-z
pii: 10.1038/s41598-020-72938-z
pmc: PMC7525436
doi:

Banques de données

ClinicalTrials.gov
['NCT00004210']

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

15959

Références

Lynch, H. T. et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 76(1), 1–18 (2009).
pubmed: 19659756 pmcid: 2846640 doi: 10.1111/j.1399-0004.2009.01230.x
Ligtenberg, M. J., Kuiper, R. P., Geurts van Kessel, A. & Hoogerbrugge, N. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam. Cancer 12(2), 169–174 (2013).
pubmed: 23264089 doi: 10.1007/s10689-012-9591-x
Barrow, E., Hill, J. & Evans, D. G. Cancer risk in Lynch Syndrome. Fam. Cancer 12(2), 229–240 (2013).
pubmed: 23604856 doi: 10.1007/s10689-013-9615-1
Win, A. K. et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol. Biomark. Prev. 26(3), 404–412 (2017).
doi: 10.1158/1055-9965.EPI-16-0693
Frankel WL, Arends MJ, Frayling IM, Nagtegaal ID. Lynch Syndrome. In: WHO Classification of Tumours Editorial Board. Digestive system tumours. 5th ed. 515–521 (International Agency for Research on Cancer, Lyon, France, 2019).
Bernhardt, B. A., Zayac, C. & Pyeritz, R. E. Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia. Genet. Med. 13(9), 812–820 (2011).
pubmed: 21637104 pmcid: 3166421 doi: 10.1097/GIM.0b013e31821d2e6d
Jarvinen, H. J. et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5), 829–834 (2000).
pubmed: 10784581 doi: 10.1016/S0016-5085(00)70168-5
de Vos tot Nederveen Cappel, W. H. et al. Colorectal surveillance in Lynch syndrome families. Fam. Cancer 12(2), 261–265 (2013).
pubmed: 23525799 doi: 10.1007/s10689-013-9631-1
Douglas, J. A. et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA 294(17), 2195–2202 (2005).
pubmed: 16264161 doi: 10.1001/jama.294.17.2195
Hadley, D. W. et al. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin. Oncol. 22(1), 39–44 (2004).
pubmed: 14701766 doi: 10.1200/JCO.2004.06.128
Halbert, C. H. et al. Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch. Intern. Med. 164(17), 1881–1887 (2004).
pubmed: 15451763 doi: 10.1001/archinte.164.17.1881
Esplen, M. J. et al. Long-term psychosocial and behavioral adjustment in individuals receiving genetic test results in Lynch syndrome. Clin. Genet. 87(6), 525–532 (2015).
pubmed: 25297893 doi: 10.1111/cge.12509
Aktan-Collan, K. et al. Psychosocial consequences of predictive genetic testing for Lynch syndrome and associations to surveillance behaviour in a 7-year follow-up study. Fam. Cancer 12(4), 639–646 (2013).
pubmed: 23512527 doi: 10.1007/s10689-013-9628-9
Bleiker, E. M., Esplen, M. J., Meiser, B., Petersen, H. V. & Patenaude, A. F. 100 years Lynch syndrome: what have we learned about psychosocial issues?. Fam. Cancer 12(2), 325–339 (2013).
pubmed: 23670341 doi: 10.1007/s10689-013-9653-8
Lindor, N. M. et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12), 1507–1517 (2006).
pubmed: 17003399 doi: 10.1001/jama.296.12.1507
Giardiello, F. M. et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am. J. Gastroenterol. 109(8), 1159–1179 (2014).
pubmed: 25070057 doi: 10.1038/ajg.2014.186
Sharaf, R. N., Myer, P., Stave, C. D., Diamond, L. C. & Ladabaum, U. Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin. Gastroenterol. Hepatol. 11(9), 1093–1100 (2013).
pubmed: 23669308 doi: 10.1016/j.cgh.2013.04.044
Ramsoekh, D. et al. The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP. Clin. Genet. 72(6), 562–567 (2007).
pubmed: 17922849 doi: 10.1111/j.1399-0004.2007.00912.x
Christiaans, I., Birnie, E., Bonsel, G. J., Wilde, A. A. & van Langen, I. M. Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. Eur. J. Hum. Genet. 16(10), 1201–1207 (2008).
pubmed: 18478037 doi: 10.1038/ejhg.2008.92
Finlay, E. et al. Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet. Test. 12(1), 81–91 (2008).
pubmed: 18373407 pmcid: 3072893 doi: 10.1089/gte.2007.0037
Aktan-Collan, K. et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int. J. Cancer 89(1), 44–50 (2000).
pubmed: 10719730 doi: 10.1002/(SICI)1097-0215(20000120)89:1<44::AID-IJC8>3.0.CO;2-3
Lerman, C. et al. Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281(17), 1618–1622 (1999).
pubmed: 10235155 doi: 10.1001/jama.281.17.1618
Giardiello, F. M. et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147(2), 502–526 (2014).
pubmed: 25043945 doi: 10.1053/j.gastro.2014.04.001
Barrow, P. et al. Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey. Clin. Genet. 87(6), 517–524 (2015).
pubmed: 25652327 doi: 10.1111/cge.12559
Hadley, D. W. et al. Perceptions of cancer risks and predictors of colon and endometrial cancer screening in women undergoing genetic testing for Lynch syndrome. J. Clin. Oncol. 26(6), 948–954 (2008).
pubmed: 18281669 doi: 10.1200/JCO.2007.13.0575
Boonyasiriwat, W. et al. Intention to undergo colonoscopy screening among relatives of colorectal cancer cases: a theory-based model. Ann. Behav. Med. Publ. Soc. Behav. Med. 47(3), 280–291 (2014).
doi: 10.1007/s12160-013-9562-y
Burton-Chase, A. M. et al. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin. Genet. 86(2), 185–189 (2014).
pubmed: 23906188 doi: 10.1111/cge.12246
Ashida, S. et al. The importance of older family members in providing social resources and promoting cancer screening in families with a hereditary cancer syndrome. Gerontologist 51(6), 833–842 (2011).
pubmed: 21562055 pmcid: 3220664 doi: 10.1093/geront/gnr049
Gimeno Garcia, A. Z., Quintero, E., Nicolas Perez, D., Hernandez, M. & JimenezSosa, A. Colorectal cancer screening in first-degree relatives of colorectal cancer: participation, knowledge, and barriers against screening. Eur. J. Gastroenterol. Hepatol. 23(12), 1165–1171 (2011).
pubmed: 21989122 doi: 10.1097/MEG.0b013e32834a289e
Vernon, S. W. Risk perception and risk communication for cancer screening behaviors: a review. J. Natl. Cancer Inst. Monogr. 25, 101–119 (1999).
doi: 10.1093/oxfordjournals.jncimonographs.a024184
Flander, L. et al. Perceived versus predicted risks of colorectal cancer and self-reported colonoscopies by members of mismatch repair gene mutation-carrying families who have declined genetic testing. J. Genet. Couns. 23(1), 79–88 (2014).
pubmed: 23748873 doi: 10.1007/s10897-013-9614-2
Collins, V., Meiser, B., Gaff, C., St John, D. J. & Halliday, J. Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer 104(2), 273–281 (2005).
pubmed: 15948171 doi: 10.1002/cncr.21183
Aktan-Collan, K., Haukkala, A., Mecklin, J. P., Uutela, A. & Kaariainen, H. Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer. J. Med. Genet. 38(11), 787–792 (2001).
pubmed: 11732490 pmcid: 1734755 doi: 10.1136/jmg.38.11.787
Bjorvatn, C. et al. Risk perception, worry and satisfaction related to genetic counseling for hereditary cancer. J. Genet. Couns. 16(2), 211–222 (2007).
pubmed: 17279329 doi: 10.1007/s10897-006-9061-4
Sivell, S. et al. How risk is perceived, constructed and interpreted by clients in clinical genetics, and the effects on decision making: systematic review. J Genet. Couns. 17(1), 30–63 (2008).
pubmed: 17968638 doi: 10.1007/s10897-007-9132-1
Menko, F. H. et al. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Fam. Cancer 18(1), 127–135 (2019).
pubmed: 29846880 doi: 10.1007/s10689-018-0089-z
Menko, F. H. et al. Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists. Fam. Cancer 12(2), 319–324 (2013).
pubmed: 23535968 doi: 10.1007/s10689-013-9636-9
Gimeno Garcia, A. Z. Factors influencing colorectal cancer screening participation. Gastroenterol. Res. Pract. 2012, 483417 (2012).
pubmed: 22190913 doi: 10.1155/2012/483417
Wang, C. et al. Family history assessment: impact on disease risk perceptions. Am. J. Prevent. Med. 43(4), 392–398 (2012).
doi: 10.1016/j.amepre.2012.06.013
Tan, Y. Y., Spurdle, A. B. & Obermair, A. Knowledge, attitudes and referral patterns of lynch syndrome: a survey of clinicians in australia. J. Pers. Med. 4(2), 218–244 (2014).
pubmed: 25563224 pmcid: 4263974 doi: 10.3390/jpm4020218
Domanska, K., Carlsson, C., Bendahl, P. O. & Nilbert, M. Knowledge about hereditary nonpolyposis colorectal cancer; mutation carriers and physicians at equal levels. BMC Med. Genet. 10, 30 (2009).
pubmed: 19323816 pmcid: 2671498 doi: 10.1186/1471-2350-10-30
Frey, M. K. et al. Knowledge of Lynch syndrome among obstetrician/gynecologists and general surgeons. Int. J. Gynaecol. Obstet. 126(2), 161–164 (2014).
pubmed: 24950908 doi: 10.1016/j.ijgo.2014.02.024
Weinstein, N. D. & Klein, W. M. Resistance of personal risk perceptions to debiasing interventions. Health Psychol. 14(2), 132–140 (1995).
pubmed: 7789348 doi: 10.1037/0278-6133.14.2.132
Hadley, D. W. et al. Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch. Intern. Med. 163(5), 573–582 (2003).
pubmed: 12622604 doi: 10.1001/archinte.163.5.573
Jasperson, K. Colorectal cancer: Cascade genetic testing in Lynch syndrome: room for improvement. Nat. Rev. Gastroenterol. Hepatol. 10(9), 506–508 (2013).
pubmed: 23835491 doi: 10.1038/nrgastro.2013.122

Auteurs

Donald W Hadley (DW)

Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, 35 Convent Drive, MSC 3717, Bldg. 35, Room 1B205, Bethesda, MD, 20892-3717, USA. dhadley@mail.nih.gov.

Dina Eliezer (D)

Social Networks Methods Section, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Yonit Addissie (Y)

Social Networks Methods Section, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Andrea Goergen (A)

Social Networks Methods Section, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Sato Ashida (S)

Department of Community and Behavioral Health, College of Public Health, University of Iowa, Iowa City, IA, USA.

Laura Koehly (L)

Social Networks Methods Section, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH